Amgen (AMGN: NASDAQ) Investor Relations Material

Overview

Amgen Inc., a global leader in biotechnology, researches, develops, manufactures, and delivers human therapeutics worldwide. The company's focus areas include inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. Amgen's impressive product portfolio boasts Enbrel, Neulasta, Prolia, Xgeva, Otezla, Aranesp, KYPROLIS, Repatha, Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The biotech giant mainly serves healthcare providers such as physicians, dialysis centers, pharmacies, and hospitals, distributing its products through pharmaceutical wholesale distributors and direct-to-consumer channels. Amgen's efforts toward innovation and collaboration are evident throughout its corporate partnerships with Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc. These partnerships have resulted in a collaboration agreement to evaluate VS-6766, in combination with lumakrastm (Sotorasib), in patients with KRAS G12C-mutant non-small cell lung cancer. Amgen also has a research and development collaboration with Neumora Therapeutics, Inc., and Plexium, Inc. Moreover, Amgen has an agreement with Kyowa Kirin Co., Ltd, to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody. Headquartered in Thousand Oaks, California, Amgen Inc. was incorporated in 1980. Amidst the changing landscape of the biotech and biopharmaceutical industries, Amgen stands out for its commitment to developing innovative treatments and fostering partnerships to create a better world.